Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
102 studies found for:    cholangiocarcinoma | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Safety Study of Liver Transplantation for Hilar Cholangiocarcinoma
Condition: Hilar Cholangiocarcinoma
Intervention: Other: liver transplantation combined with neoadjuvant therapy
22 Recruiting Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma
Condition: Cholangiocarcinoma
Intervention: Radiation: Therasphere® in association with Gemcitabine and Cisplatin
23 Recruiting A Phase I/II Study Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas
Condition: Cholangiocarcinoma
Interventions: Drug: Amphinex and Gemcitabine;   Drug: Gemcitabine and Cisplatin
24 Recruiting Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
Conditions: Intrahepatic Cholangiocarcinoma;   Peripheral Cholangiocarcinoma;   Cholangiolar Carcinoma;   Cholangiocellular Carcinoma
Interventions: Drug: Floxuridine (FUDR);   Drug: dexamethasone;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Other: MRI;   Other: Research blood draws
25 Recruiting RFA RCT for Pancreatic or Bile Duct Cancer
Conditions: Unresectable Pancreatic Cancer;   Cholangiocarcinoma Non-resectable
Interventions: Procedure: Radiofrequency Ablation using EndoHPB Probe;   Procedure: Stenting only
26 Recruiting Liver Resection Versus Radio-chemotherapy-Transplantation for Hilar Cholangiocarcinoma
Conditions: Cholangiocarcinoma;   Morphological Diagnosis of Hilar Cholangiocarcinoma (Excluded Type 1), Resectable With Expected R0 Margins on an intent-to Treat Basis.
Interventions: Procedure: CAPECITABINE-Radiotherapy -Liver Transplantation;   Procedure: RESECTION
27 Recruiting Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma
Conditions: Intrahepatic Cholangiocarcinoma;   Peripheral Cholangiocarcinoma;   Cholangiolar Carcinoma;   Cholangiocellular Carcinoma) (ICC)
Interventions: Procedure: Liver resection and placement of hepatic artery infusion pump;   Drug: FLOXURIDINE;   Drug: DEXAMETHASONE;   Drug: GEMCITABINE
28 Recruiting A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Condition: Metastatic Biliary Tract Carcinoma
Intervention: Drug: Regorafenib
29 Recruiting Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Conditions: Solid Tumors;   Thyroid Cancer;   Soft-tissue Sarcoma;   Cholangiocarcinoma
Interventions: Drug: Pazopanib;   Drug: GSK1120212
30 Recruiting S-1 in Combination With Abraxane in Treating Cholangiocarcinoma
Condition: Cholangiocarcinoma
Intervention: Drug: S-1 plus Abraxane
31 Recruiting CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
Conditions: Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Extrahepatic Bile Duct Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Intervention: Drug: 6,8-bis(benzylthio)octanoic acid
32 Recruiting A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection
Condition: Cholangiocarcinoma
Intervention: Drug: Gemcitabine
33 Recruiting Regorafenib Versus Placebo to Treat Cholangiocarcinoma
Condition: Cholangiocarcinoma
Interventions: Drug: Regorafenib/active;   Drug: Regorafenib/placebo
34 Not yet recruiting A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma
Condition: Cholangiocarcinoma
Intervention: Drug: LDK378
35 Recruiting IRS(Irradiation Stent) vs. CS(Conventional Stent) Insertion in Inoperable Malignant Biliary Obstruction
Condition: Cholangiocarcinoma
Interventions: Procedure: Stenting;   Device: self-expandable metallic biliary stent loaded with 125 iodine seeds;   Device: conventional biliary self-expandable stent;   Procedure: brachytherapy
36 Recruiting Endobiliary RFA for Unresectable Malignant Biliary Strictures
Conditions: Cholangiocarcinoma;   Ampullary Carcinoma
Intervention: Procedure: Radiofrequency ablation (RFA)
37 Recruiting Treatment for Bile Duct Cancer in the Liver
Condition: Cholangio Carcinoma
Intervention: Drug: SIRT Yttrium-90
38 Recruiting Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma.
Condition: Cholangiocellular Carcinoma
Intervention: Drug: Cisplatin and Gemcitabine
39 Recruiting Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).
Condition: Intrahepatic Cholangiocellular Carcinoma
Interventions: Procedure: DEB TACE;   Procedure: SIRT
40 Recruiting Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin
Condition: Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Device: LC Bead with Gem-Cis;   Drug: Gemcitabine and Cisplatin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years